Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 4, 2025

Brilliant Violet 605(TM) anti-mouse CD366 (Tim-3)

RRID:AB_2616907
Type: Antibody

Proper Citation

(BioLegend Cat# 119721, RRID:AB_2616907)

Antibody Information

URL: http://antibodyregistry.org/AB_2616907

Proper Citation: (BioLegend Cat# 119721, RRID:AB_2616907)

Target Antigen: CD366

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse CD366 (Tim-3)

Description: This monoclonal targets CD366

Target Organism: mouse

Clone ID: Clone RMT3-23

Antibody ID: AB_2616907

Vendor: BioLegend

Catalog Number: 119721

Record Creation Time: 20231110T034919+0000

Record Last Update: 20240725T100251+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse CD366 (Tim-3).

No alerts have been found for Brilliant Violet 605(TM) anti-mouse CD366 (Tim-3).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell, 187(9), 2288.

Gubser PM, et al. (2024) Aerobic glycolysis but not GLS1-dependent glutamine metabolism is critical for anti-tumor immunity and response to checkpoint inhibition. Cell reports, 43(8), 114632.

Andrews LP, et al. (2024) LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell, 187(16), 4355.

Swaminathan S, et al. (2024) LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. Cell reports, 43(3), 113879.

Rao Y, et al. (2024) The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma. iScience, 27(5), 109668.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med (New York, N.Y.), 5(10), 1237.

Gao T, et al. (2024) Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models. Cell reports. Medicine, 5(5), 101513.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell, 187(16), 4336.

Beltra JC, et al. (2023) Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. Immunity, 56(12), 2699.

Osorio JC, et al. (2023) The antitumor activities of anti-CD47 antibodies require Fc-Fc?R interactions. Cancer cell, 41(12), 2051.

Muñoz-Ruiz M, et al. (2023) IFN-?-dependent interactions between tissue-intrinsic ?? T cells and tissue-infiltrating CD8 T cells limit allergic contact dermatitis. The Journal of allergy and clinical immunology, 152(6), 1520.

Ramirez-Valdez RA, et al. (2023) Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell reports, 42(6), 112599.

Zhao K, et al. (2023) The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice. Frontiers in immunology, 14, 1101769.

Ramachandran M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell, 41(6), 1134.

Baxter AE, et al. (2023) The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. Immunity, 56(6), 1320.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer cell, 41(2), 235.

Gaglia G, et al. (2023) Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer cell, 41(5), 871.

Fernández-García J, et al. (2022) CD8+ T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation. Cell reports, 41(7), 111639.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell reports, 41(7), 111647.

Baharom F, et al. (2022) Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell, 185(23), 4317.